Harbour Biomed News and Activities
Presence
Headquarters: China
Harbour Biomed is a company listed under the stock ticker 2142 (CN).
Acquisition, funding and merger involving Harbour Biomed.
- Harbour Biomed has just announced a $90 Million fundraising (posted on December 26 2025).
Executives
View the org chart displaying its 17 main executives
Most searched biographies at Harbour Biomed
- Jingsong Wang, Executive Director, Chairman of the Board and Chief...
- Robert Kamen, Independent Non-Executive Director
- Albert Collinson, Independent Non-Executive Director
Popular executive movements at Harbour Biomed
- Jenny Xie has joined the company as Chief Scientific Officer, Immunology and Head of Global External Innovation (posted on March 19 2026).
Create your alert
to follow the executive moves at Harbour Biomed.
Biotechnology
Harbour Biomed has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- Ona Therapeutics has just announced a $87 Million fundraising (posted on June 5 2026).
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
Popular contacts in Biotechnology
News
Press releases by Harbour Biomed
- Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology-HBM Holdings
- Harbour BioMed and Evinova China Announce Strategic AI Collaboration to Accelerate AI-Enabled Drug Development-HBM Holdings
- Harbour BioMed Launches First Fully Human Generative AI HCAb Model to Accelerate Next-Generation Biologics Discovery-HBM Holdings
- Harbour BioMed Announces Positive Phase II Results for HBM4003 and Tislelizumab Combination in MSS mCRC-HBM Holdings
- Harbour BioMed Reports 2025 Interim Results-HBM Holdings
- Harbour BioMed Appoints Yajie Li as Chief Medical Officer-HBM Holdings
- HBM9378/WIN378, a Long-Acting, Fully Human Anti-TSLP Antibody, Enters Global Phase 2 POLARIS Trial for Asthma-HBM Holdings
- Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers-HBM Holdings
- China National Intellectual Property Administration Affirms Validity of Harbour BioMed’s Patent; Infringement Lawsuit Moves Forward-HBM Holdings
- Harbour BioMed Appoints Youchen Chen as Chief Financial Officer-HBM Holdings
- View more press releases Close
Social media about Harbour Biomed
- Harbour Biomed on Wikipedia, Google News & Yahoo Finance
- Harbour Biomed on LinkedIn, X (Twitter) & YouTube
